Nexalin Technology, Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you understand Nexalin Technology’s performance over the past year. My goal is to explain their complex filings in plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Nexalin is a Houston-based medical device company. They create non-invasive, drug-free neurostimulation technology to treat mental health conditions like anxiety, depression, and insomnia. They are currently in a high-stakes "growth phase," spending heavily on research and clinical trials to prove their new devices work and to secure mass-market approval. In 2023, the company focused its capital on developing its Generation 2 (Gen-2) and Generation 3 (Gen-3) devices.

2. Financial performance

Nexalin is currently "pre-revenue" for its new products. They reported total revenue of about $14,000 for 2023, compared to $12,000 in 2022. Their income comes from small fees for older "Gen-1" devices still in use. To build future income, their new devices use "smart" technology that requires a new, proprietary electrode for every treatment. Think of it like a printer company that gives away the printer but makes its money on the ink cartridges. This ensures recurring revenue once they launch. Currently, the company is losing money, reporting a loss of about $11.9 million for 2023, compared to $10.1 million in 2022.

3. Major wins and challenges

• The Virtual Clinic Model: They are moving toward a model where a doctor diagnoses a patient via telehealth, and Nexalin ships a headset directly to their home. This avoids the stigma of visiting a psychiatrist.
• Global Reach: They have regulatory approval in Brazil and Oman and are targeting the U.S. military for PTSD treatment.
• The U.S. Transition: They stopped selling Gen-1 devices in the U.S. while waiting for FDA approval for their more powerful 15-milliamp technology. This transition has temporarily halted U.S. sales.

4. Financial health

This is the most critical section. The company reported "material weaknesses" in their accounting, specifically a lack of staff with the right technical expertise. They are burning through cash to fund research, with only about $2.6 million in cash left as of December 31, 2023. Because they spend cash quickly, they will likely need to sell more shares soon, which would dilute your ownership. They are also fighting to keep their stock price above $1.00 to maintain compliance with Nasdaq requirements through July 2026.

5. Key risks

• Regulatory Roadblocks: Their business depends on FDA approval. If the FDA demands more trials, the company could run out of cash, as they have limited funds to operate beyond the next 12 months without new financing.
• International Risks: They have a joint venture in China. While they have no active operations there, they face complex data laws and geopolitical tensions.
• Delisting Risk: If the stock stays below $1.00, they face removal from the Nasdaq, which would make it harder to trade shares and raise money.

6. Competitive positioning

Nexalin aims to replace pharmaceuticals with their headset. Their edge is their "15-milliamp waveform" technology, which they claim is more effective than older devices. Their "smart" electrode system prevents competitors from selling cheaper, generic parts, supporting their "razor-and-blade" business model.

7. Future outlook

The company is currently in the early stages of seeking FDA approval for their Gen-2 device. Success depends on proving their technology is safe and effective. They are also exploring a potential partnership with GreenLight Venture LLC for capital or distribution.

Investor Takeaway: Nexalin is a high-risk, speculative play. They are essentially a research-heavy startup with very little current revenue and a significant need for more cash. If you are considering an investment, weigh the potential of their "smart" electrode technology against the very real risks of share dilution, regulatory hurdles, and the need for additional funding to keep the lights on.